The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

A slower ramp-up of Kisunla dosing lowers the rate of dangerous brain swelling, a risk that has made doctors reluctant to ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value for money”.

Japanese authorities are putting Eisai (TYO: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The ...

Eli Lilly has won a green light from the FDA for new dosing for its Alzheimer's disease therapy Kisunla, which carries a ...

INmune Bio's Alzheimer's drug XPro showed targeted benefits in patients with brain inflammation, but misses the main trial ...

In the case of the amyloid drugs, Eisai Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab) – there are also ...

HATFIELD, HERTFORDSHIRE, UNITED KINGDOM (UK), and MAIDENHEAD, UK, 7 JULY 2025 – Eisai Europe Ltd. and Biogen Idec Ltd. announced today that the Scottish Medicines Consortium (SMC) has not recommended ...